MedTrace Logo

A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia

NCT05930028 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2024-10-18

No results posted yet for this study

Summary

The objective of this clinical study is to evaluate the efficacy and safety by comparing BR1017A+BR1017B treatment group to BR1017A treatment group and BR1017B treatment group respectively at Week 8 in essential hypertension patients with primary hypercholesterolemia

Conditions

  • Essential Hypertension
  • Primary Hypercholesterolemia

Interventions

DRUG

Fimasartan

Subjects take the investigational products once a day for 8 weeks.

DRUG

Ezetimibe/Atorvastatin

Subjects take the investigational products once a day for 8 weeks.

DRUG

Fimasartan Placebo

Subjects take the investigational products once a day for 8 weeks.

DRUG

Ezetimibe/Atorvastatin Placebo

Subjects take the investigational products once a day for 8 weeks.

Sponsors & Collaborators

  • Boryung Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-13
Primary Completion
2024-09-05
Completion
2024-09-05

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05930028 on ClinicalTrials.gov